Eupraxia to Present Phase 2 Osteoarthritis Study Data at EULAR 2024

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology firm, announced that the findings from its Phase 2 study of EP-104IAR for treating knee osteoarthritis will be showcased at the European Congress of Rheumatology 2024, organized by the European Alliance of Associations for Rheumatology (EULAR). This event will take place in Vienna, Austria, from June 12-15, 2024.

The company's core technology, DiffuSphere™, is a polymer-based micro-sphere system designed to optimize drug delivery with extended effects and minimal side effects. This technology can be adapted for various active pharmaceutical ingredients and delivery systems, making it versatile for different therapeutic applications.

Eupraxia recently concluded a Phase 2b clinical trial, named SPRINGBOARD, for EP-104IAR, aimed at alleviating knee osteoarthritis pain. The trial achieved its primary endpoint and three out of four secondary endpoints. Additionally, Eupraxia has extended the use of its EP-104 platform into gastrointestinal disorders. This includes a Phase 1b/2a trial named RESOLVE, focusing on eosinophilic esophagitis.

The company is also developing a range of long-acting formulations for both early and late stages of clinical development. These formulations could potentially address other inflammatory joint conditions and even oncology. Each candidate aims to improve the safety, efficacy, and tolerability of existing treatments.

Eupraxia's mission is to develop locally delivered, extended-release products that meet high unmet medical needs. By offering targeted, long-lasting activity with fewer side effects, the company hopes to provide significant benefits to patients. Their investigational technology is engineered to offer multiple pharmacokinetic profiles, making it highly adaptable.

The announcement also shared forward-looking statements, which include expectations about the company's research, product candidates, and potential industry impact. These statements are based on current assumptions and expectations from Eupraxia's management but are subject to various risks and uncertainties.

Risks include the company's limited operating history, market acceptance of its technology, potential breaches of third-party licensing agreements, regulatory challenges, and reliance on third-party suppliers and research organizations. Additionally, there are concerns regarding the company's ability to secure future funding and the lengthy, uncertain regulatory requirements for new therapeutics.

Eupraxia has acknowledged these challenges and emphasized that while they strive to mitigate risks, there are no guarantees. The company remains committed to updating stakeholders as new information becomes available, in compliance with applicable securities laws.